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Abstract
Heart transplant remains the gold standard treatment for end-stage heart failure, in spite 
of the recent advances in pharmacological treatment and device therapy. As expected, 
since the first heart transplant was performed 50 years ago, outcomes in heart transplant 
have continued to improve over the last decades focusing on perioperative management, 
the availability of newer and better mechanical circulatory support before and after heart 
transplant and immunosuppressive drug development. Nonetheless, in the last years 
we have witnessed a significant drop in the heart donor’s pool as the greatest limiting 
factor, coupled with a rising number of advanced heart failure patients. Moreover, the 
difficulty in handling these patients, with multiple and more complex comorbidities, is 
continuously increasing. More importantly and despite these difficulties, conditional 
half-life in transplanted patients has nowadays reached 12 years of life expectancy. Thus, 
besides trying to increase donor numbers, candidate selection emerges as one of the most 
challenging issues for heart transplant programs. In this chapter we review the latest 
knowledge on indications for heart transplant, as well as the available screening and 
optimization tools in candidate selection in order to continue improving outcomes.
Keywords: heart transplant, indications, advanced heart failure, ventricular assist 
device
1. Introduction
Heart transplant (HTx) is indicated in patients with stage D heart failure (HF) who remain with 
severely disabling symptoms in spite of optimal medical and device treatment, and where 
other surgical options have been excluded [1]. In patients with progressive HF, treatment 
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optimization by selection and up-titration of appropriate drugs (e.g., beta-blockers and inhib-
itors of the renin-angiotensin-aldosterone axis), device implantation (resynchronization ther-
apy, implanted cardioverter defibrillator), and surgical intervention if appropriate (e.g., valve 
replacement in case of valve disease) becomes mandatory. Only in cases where conventional 
HF treatment is not well tolerated and/or the patient presents an unfavorable course we will 
raise the option of HTx. At this point, it is useful to recognize the clinical and hemodynamic 
parameters that identify patients in an advanced-HF (AHF) situation (Table 1), which repre-
sents 5% of the total number of patients in HF [2]. In the case of patients in cardiogenic shock 
(CS), the priority is to get the patient out of the shock situation and correct multi-organ fail-
ure, for which we will usually need inotropic and vasoactive treatment, intra-aortic balloon 
counterpulsation and, in some cases, ventricular mechanical assistance devices (VAD). Once 
the patient is stable, we will have to attempt to wean the VAD, if we consider that myocardial 
recovery is an option, or HTx otherwise.
The long waiting times and the increasing number of unstable patients have favored the devel-
opment of mechanical circulatory support (MCS) therapies as bridge to transplant (BTT) and 
bridge to candidacy or decision (BTC/BTD). This was initially achieved by the use of short-
term ventricular assist devices (STVADs), but in the last decades long-term ventricular assist 
1. Severe symptoms of heart failure with dyspnea and/or fatigue at rest or on minimal exertion (NYHA functional 
class III or IV)
2. Episodes of fluid retention (pulmonary and/or systemic congestion, peripheral edema) and/or of reduced cardiac 
output at rest (peripheral hypoperfusion)
3. Objective evidence of severe cardiac dysfunction, shown by at least 1 of the following
a. Low left ventricular ejection fraction (<30%)
b. Pseudonormal or restrictive mitral inflow pattern on Doppler echocardiography
c. High left ventricular filling pressures (mean PCWP >16 mmHg, and/or mean RAP >12 mmHg by pulmonary 
artery catheterization)
d. High natriuretic peptide levels, in the absence of non-cardiac causes
4. Severe impairment of functional capacity shown by 1 of the following:
a. Inability to exercise
b. 6-minute walk test ≤300 m or less in females and/or patients aged ≥75 years
c. Peak oxygen consumption <12 to 14 mL/kg/min
5. History of ≥1 heart failure hospitalization in the past 6 months
6. Presence of all the previous features despite “attempts to optimize” therapy including diuretics, renin-
angiotensin-aldosterone system inhibitors, and beta-blockers, unless these are poorly tolerated or contraindicated, 
and cardiac resynchronization when indicated
NYHA: New York Heart Association; PCWP: pulmonary capillary wedge pressure; RAP: right atrial pressure.
Table 1. Definition of advanced heart failure according to ESC (Adapted from Metra et al. [2]).
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devices (LTVADs) have been developed and allow for longer periods of support. Because 
recovery of the ventricular dysfunction is possible, especially in some settings such as myo-
carditis or acute coronary syndrome, the bridge to recovery (BTR) strategy is another option. 
Finally, the development of more reliable LTVADs has created the possibility of destination 
therapy (DT) in patients who are not candidates for HTx because of significant comorbidities. 
In this chapter we will focus our attention in the use of LTVADs as a bridge to transplant.
When evaluating a patient for HTx, we must assess the following aspects:
1. What is the expected mortality of the HF patient with the maximal surgical and medical 
treatment options?
2. What is the risk of performing a HTx? Which are the potential complications derived from 
the medical and immunosuppressive treatment after the intervention?
3. Who is the appropriate candidate? When should we put the patient on the waiting list for 
HTx?
4. How can we optimize our patient before HTx in order to improve post-operative outcomes?
2. Assessing prognosis of the patient with HF
In spite of the recent treatment advances, HF mortality is expected to be around 10% per 
year in large randomized studies [3], with a median survival of approximately 2 years in 
unselected cohorts [4]. Because mortality during the first year post-HTx ranges between 12 
and 20% and the median of survival of the heart transplant is 12 years [5], it is important 
to carry out an adequate prognostic stratification in order to select those patients who will 
obtain the maximum benefit from HTx. Along these lines, we will review the most important 
clinical features and risk factors that should direct clinicians to undergo an early and com-
prehensive evaluation, and confirm if the patient is an appropriate candidate for the avail-
able advanced therapies, before a more severe deterioration is present and treatment options 
become compromised.
2.1. Clinical parameters
Multiple clinical parameters are associated with higher mortality in HF patients. During the last 
years, there has been a considerable effort by clinicians to define the common characteristics 
of AHF, and these can be seen in Table 1. For instance, progressive treatment intolerance, per-
sistent clinical signs of HF, echocardiographic and hemodynamic signs of low output, multi-
organ involvement and repeated hospitalizations, severely compromise patients’ prognosis [6].
2.2. Etiology of heart failure
Ischemic cardiomyopathy has traditionally been associated with higher mortality, especially 
when severe left ventricular dysfunction and three-vessel or main stem left coronary artery 
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disease unsuitable for revascularization is present [7]. Congenital heart diseases are also asso-
ciated with greater mortality because of the higher degree of pulmonary arterial hypertension 
and possible previous cardiac surgeries [5]. Therefore, we recommend referring these patients 
to specific transplant centers with congenital heart disease expertise.
Cardiomyopathies are disorders in which the heart muscle is structurally and functionally 
abnormal in the absence of other causes such as coronary artery disease, arterial hypertension, 
valvular heart disease, congenital heart disease or any other condition that may cause abnor-
mal loading conditions. In idiopathic dilated cardiomyopathies, the presence of a higher degree 
of fibrosis demonstrated by delayed gadolinium enhancement in cardiac magnetic resonance 
(MRI) is associated with worse prognosis and sudden death [8]. T1 and T2 mapping are MRI-
based techniques that are able to measure the extracellular volume in the heart, which have also 
been shown to correlate with prognosis in patients with HF and cardiomyopathies [9].
Moreover, a non-negligible number of patients are affected by familial dilated cardiomyopa-
thy (DCM), which can sometimes be easily identified with a simple family pedigree [10]. On 
this subject, with the advent of next generation sequencing gene techniques, we are now able 
to identify multiple mutations associated with DCM in more than 50 genes [11]. The most fre-
quent ones are titin (TTN), lamin (LMNA) and desmin (DES). Pathogenic mutations in LMNA 
[12] and DES [13] as well as filamin C (FLNC) [14] genes are specifically related with frequent 
arrhythmias and subsequent worse prognosis. Therefore, genetic testing should also be taken 
into account when stratifying patients, especially because they usually affect young individu-
als, with less evident HF symptoms in spite of the severe myocardial disease.
The indication for HTx in patients with hypertrophic cardiomyopathy (HCM) is unusual and 
should be reserved for patients with persistent marked symptoms, after all therapeutic pos-
sibilities have been applied, including septal reduction techniques. It is more frequent to per-
form HTx in patients with HCM with progressive severe left ventricular dysfunction and/or 
a restrictive pattern.
Arrhythmogenic cardiomyopathy is produced by the alteration of cardiac desmosomes, 
which predisposes to an abnormal response to mechanical stress. Genetically, it is transmit-
ted predominantly in an autosomal dominant manner with a variable clinical expression and 
an incomplete penetrance that is dependent of age. It is a frequent cause of sudden death and 
ventricular arrhythmias, especially in young adults and athletes, because it is linked to severe 
ventricular arrhythmias, especially when it affects the left ventricle. Furthermore, in spite of 
the use of implantable cardiac defibrillators (ICD), severe cardiac events including sudden 
cardiac death and mortality might appear over time, because of progressive biventricular 
dysfunction and untreatable arrhythmias. Hence, HTx should always be taken into account 
during follow-up [13, 14].
Restrictive cardiomyopathy (RCM) is the least common and it comprises a group of diseases 
of the myocardium, characterized by a rigid myocardium that produces diastolic dysfunction 
that leads to a restrictive physiology, with a normal or reduced systolic and diastolic ven-
tricular volumes and non-thickened or minimally thickened ventricular walls. The majority 
of the restrictive cardiomyopathies can be secondary to a toxic process (e.g., radiotherapy, 
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hypereosinophilic syndrome, use of anthracyclines), infiltrative disease (e.g., amyloido-
sis or sarcoidosis), and storage cardiomyopathy (Anderson-Fabry disease, Danon disease, 
hemochromatosis) with amyloidosis being the most common etiology. Nonetheless, genetic 
restrictive cardiomyopathy is also a diagnostic possibility that should be taken into account, 
especially when family involvement is present. In this regard, DES mutations are charac-
terized by severe diastolic dysfunction and atrio-ventricular block, with progressive systolic 
dysfunction and early-onset end-stage HF, and frequent neuromuscular disease.
In regards to amyloidosis, it is important to distinguish between the different types of amyloid 
deposit because of the different prognosis and treatment strategies. In immunoglobulin light 
chain amyloidosis (AL or primary amyloidosis) the evolution of HF is very fast, and although 
HTx is feasible, significant involvement of other organs should be ruled out. Nonetheless, 
HTx outcomes are significantly worse, even with bone marrow transplant, and survival rates 
reach 82% and 65% at 1 and 5 years, respectively [15, 16]. In cases of hereditary transthyretin 
amyloidosis, HF does not progress as rapidly as in light chain amyloidosis, and it is recom-
mended to perform HTx followed by liver transplant at a second time point to prevent further 
myocardial compromise, although the advent of new drugs to treat transthyretin amyloid 
and the different mutations involved may change this strategy. In any case, it is also essential 
to exclude severe amyloid involvement of other organs [17].
Among the different types of cardiomyopathies, serious multi-organ involvement, particu-
larly neuromuscular involvement that could compromise the respiratory capacity should 
always be ruled out. Thus, the decision to go to HTx must be taken after a comprehensive 
multidisciplinary evaluation that should involve at least, a HF specialist, a pneumologist and 
a neurologist.
2.3. Functional capacity
Clinical assessment of functional capacity is a subjective measure of the patient’s ability to 
perform daily activities that can easily be obtained, and correlates with the severity of the 
disease. It is measured by the New York Heart Association (NYHA) scale, which stratifies four 
groups (functional class) from less to more limitations in physical activity. Candidates for 
HTx are most of the time in functional class IV despite optimal medical treatment (stage D of 
the American Heart Association classification), although they can alternate with some periods 
of partial recovery to functional class III.
In spite of its usefulness, this scale is a subjective measure that an change depending on the 
patient and physician’s interpretation, and should be complemented by the use of more objec-
tive tests. The cardiopulmonary exercise test (CPET) measures peak oxygen uptake (VO2), 
which is the most accurate measure of exercise capacity and cardiopulmonary performance 
[18]. According to the latest guidelines, a peak VO2 ≤ 14 mL/kg/min or peak VO2 ≤ 12 mL/kg/
min in the presence of β-blockers at maximal exertion should be used to include patients in 
HTx list, although this should not be the unique parameter. In cases of a sub-maximal cardio-
pulmonary exercise test, defined as the ratio of carbon dioxide output/oxygen uptake (also 
called respiratory exchange ratio [RER]) < 1, the use of ventilation to carbon dioxide slope 
(VE/VCO2) > 35 is also useful because of its prognostic value [19].
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Also, the 6-minute walking test (6’WT) measures the distance that the patient is able to walk 
in 6 minutes and is useful when a cardiopulmonary test is not available. A walking distance 
of less than 300 m is associated with an annual mortality above 50% [20], and is one of the 
criteria of AHF.
2.4. Risk scores
Currently, there are several risk scores available that might help in patient stratification, and 
give support in decision making. In ambulatory patients, there are two risk scores that com-
plement the prognostic information obtained from CPET:
1. The Seattle Heart Failure Model (SHFM) has 21 variables; it is derived from a study of 
1125 patients with NYHA class IIIB or IV, during the Prospective Randomized Amlodipine 
Survival Evaluation (PRAISE) [21]. It was used in the REMATCH trial cohort for predicting 
1-year mortality in the medical and LTVAD groups with good accuracy [22]. The model 
was also prospectively validated in five additional cohorts consisting of 9942 HF patients 
and 17,307 person-years of follow-up [23]. When an estimated 1-year survival of less than 
80% is obtained, patients should be considered for HTx [19].
2. The Heart Failure Survival Score (HFSS) is calculated with the following variables: VO2 
max, ejection fraction of the left ventricle, sodium, mean arterial pressure, ischemic eti-
ology, resting heart rate, QRS > 120 ms. Patients in the medium and high risk category 
should be considered for advanced-HF therapies such as HTx listing or VAD implanta-
tion [24].
The Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) is a 
database created in 2006, with information of more than 15,000 patients who received an MCS 
[25]. The INTERMACS classification was created from this registry and helps to stratify patients 
in an AHF situation, see Table 2. In this regard, patients in a higher INTERMACS profile 
(1 or 2) seem to have worse post-HTx outcomes than those in better pre-operative condition 
(INTERMACS 3-4) [26].
2.5. Hemodynamic parameters
Pulmonary hypertension (PHT) is defined by a mean pulmonary arterial pressure greater 
than 25 mmHg, and usually develops in response to a passive backward transmission of 
elevated filling pressures from the left ventricle. Nonetheless, irreversible PHT might eventu-
ally develop in response to chronic elevated pressures that cause vascular remodeling, and 
is closely related to primary graft failure (PGF) due to right ventricular failure (RVF), which 
carries an elevated mortality after HTx [28]. Therefore right heart catheterization is recom-
mended before HTx and should be done periodically, every 3–6 months [19], especially if 
reversible PHT has been previously confirmed.
The main direct (measured directly during procedure) and indirect (calculated from direct 
parameters) parameters evaluated during right heart catheterization are:
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• Direct parameters: 1-right atrial pressure, 2-sistolic pulmonary arterial pressure (SPAP), 
3-mean pulmonary arterial pressure (MPAP), 4-pulmonary capillary wedge pressure 
(PCWP), and 4-cardiac output (CO).
• Indirect parameters: 1-transpulmonary gradient (TPG): Defined as the difference between 
mean pulmonary arterial pressure and capillary wedge pressure (TPG = MPAP-PCWP), 
2-pulmonary vascular resistance (PVR) defined as TPG/CO is usually expressed in Wood 
units, 3-cardiac index expressed as the result of CO/body surface area.
Reversible PHT is defined as a drop in SPAP ˂ 50 mmHg, TPG ˂ 12 mmHg and PVR ˂ 3 
Woods units after optimization of cardiac index and loading conditions (indicated mainly 
by central venous pressure, systemic vascular resistance and systemic arterial pressure) by 
the use of intravenous diuretics, inotropes and vasodilators, if necessary. A combination of 
inotropes with direct vasodilators (e.g., dobutamine and nitroprusside) and selective vasodi-
lators (e.g., sildenafil, nitric oxide) is also commonly used. It is important to mention that if 
after the pulmonary vasodilation test the PVR drops <3 UW but the systolic blood pressure 
falls to less than 85 mmHg, there is still a high risk of PGF after HTx [29, 30].
In any case, but especially when irreversible or fixed PHT is present, it is important to rule 
out concomitant pulmonary disease, obstructive sleep apnea syndrome or chronic pulmonary 
INTERMACS level Description 1 year survival with 
LTVAD
1. Cardiogenic Shock (“crash and 
burn”)
Hemodynamic instability with increasing inotropic 
and vasopressor support, and critical hypoperfusion of 
target organs.
52.6 ± 5.6%
2. Progressive decline despite 
inotropic support (“sliding fast” on 
inotropes)
Dependent on inotropic support but continues with 
signs of clinical deterioration (worsening renal failure, 
nutritional depletion, and inability to restore volume 
balance).
63.1 ± 3.1%
3. Stable but inotrope-dependent 
(“dependent stability“)
Stable with low/intermediate doses of inotropes, but 
necessary due to arterial hypotension, progressive renal 
failure, worsening symptoms
78.4 ± 2.5%
4. Resting symptoms on oral 
therapy (“frequent flyer“)
Patient at home on oral therapy but with high doses of 
diuretics and frequent symptoms of congestion at rest 
or with regular activity
78.7 ± 3%
5. Exertion intolerant 
(“housebound“)
Comfortable at rest but unable to engage in any activity 93 ± 3.9%
6. Exertion limited (“walking 
wounded“)
Comfortable at rest and without symptoms during 
daily living activities, but who becomes symptomatic 
with any meaningful physical exertion
7. Advanced NYHA class III 
(“placeholder“)
Patient in NYHA class III with no recent episode of 
acute decompensation
NYHA: New York Heart Association.
Table 2. INTERMACS patient profile (Source Ponikowsky et al. [27]).
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thromboembolism. If there is no responsible pulmonary disease, there are several studies 
that have shown that the chronic use of bosentan or sildenafil might reduce PHT and acheive 
reversibility of PHT after 3–4 months of this therapy [31]. If despite an appropriate vasodi-
lator treatment there is no reversibility of the PHT, LTVAD therapy should be considered, 
together with selective vasodilator treatment (usually sildenafil) [32].
3. Ventricular assist devices as bridge to transplant
MCS has largely evolved over the last years and nowadays it constitutes a real option for 
patients in AHF situation, especially in those who are in INTERMACS 1 to 4 profiles. As a 
matter of fact, in 2000, the International Society of Heart and Lung Transplantation (ISHLT) 
reported that 19.1% of HTxs were mechanically supported, and by the year 2012 this number 
had increased to 41% [33]. Lately, the clinical outcomes of a Spanish registry of 291 patients 
supported by STVAD as a BTT strategy have been published, showing an overall survival 
rate from listing to hospital discharge of 61%, and 1-year survival after listing of 58% [34]. 
Although there was a significant mortality rate, it is important to mention that the majority 
of patients were in an emergency situation (INTERMACS 1-2) and were supported by a very 
heterogeneous group of STVADs. Accordingly, it seems reasonable to use LTVADs as a BTT 
strategy at an early stage of the disease (INTERMACS 3-4) to improve HTx outcomes.
Irrespective of the design, LTVAD unloads the heart by pumping blood from the left ventricle 
to the aorta. Technology of LTVADs has been continuously evolving since the creation of the 
first generation devices, which had a diaphragm and unidirectional valves to replicate the pul-
satile cardiac cycle. The HeartMate XVE was approved by the FDA; first as BTT in 1998 and 
in 2002 as a DT, after the publication of the REMATCH trial. Later advances in technology 
have been directed to minimize the size of the pump and to increase its durability. Nowadays, 
continuous flow LTVADs have substituted pulsatile devices; these utilize a permanent mag-
netic field designed to rapidly spin a single impeller supported by mechanical, hydrodynamic 
or magnetic bearings. In second-generation continuous flow LTVAD the impeller outflow is 
directed parallel to the axis of rotation (e.g., Heartmate II, Thoratec and Incor, Berlin Heart) 
while in the third generation devices the impeller outflow is directed perpendicular to the axis 
of rotation (e.g., HVAD, Medtronic and HeartMate 3, Abbot). Third generation pumps have 
lower risk of suction events, more pulsatile waveform, and more precise flow estimation than 
second-generation pumps, but pump flow has a higher dependency on loading conditions [35].
The best candidates for a BTT strategy are patients in INTERMACS 3-4 profile; especially 
if a long waiting time for HTx is expected, as it avoids further deterioration, allows clini-
cal optimization, and provides a better quality of life. In this regard, some factors that may 
increase the difficulty in finding a appropriate donor should be taken into consideration, as 
for example previous allosensitization or large body size.
BTC LTVAD strategy is the preferred option for those patients with relative contraindica-
tions to HTx that could be potentially reversible with hemodynamic support. For instance, 
most patients with initially irreversible PHT reach reversibility or even normal pulmonary 
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pressure after some months with LTVAD [24]. In a similar fashion, renal dysfunction due 
to cardiorenal syndrome can improve enough to consider HTx. In this group, we can also 
include patients with recently diagnosed cancer or obesity (BMI > 35 kg/m2), in which the 
implantation of a LTVAD could give them time to re-evaluate candidacy.
Regarding LTVAD as DT, one of the limitations of this strategy is the increase in adverse events 
associated with long-term use of LTVAD. The ROADMAP study took a sample of 200 patients 
in INTERMACS 4–7 and divided them into two groups: optimal medical management (OMM) 
or OMM plus LTVAD. The final result showed an improvement in functional capacity in the 
second group but with a significant increase in adverse events, especially hemorrhagic compli-
cations [36]. Although current indications for DT consider a more advanced profile of patients 
(criteria derived from the REMATCH and HeartMate II DT trials [37]), the results of the 
ROADMAP study give us and idea of the advantages and disadvantages of the use of LTVAD 
as DT, further supporting the fact that HTx remains the ideal therapy in this population.
Regardless of the selected strategy, the most important fact is to ensure a correct selection 
of candidates for LTVAD implantation. One of the tools used to predict outcomes of these 
patients using mechanical support is the HeartMate II Risk Score, which is derived from an 
analysis of the HeartMate II registry. Briefly, it is based on five variables (age, serum albumin, 
creatinine, INR, and center volume of LVAD) used to create an equation that predicts mor-
tality at 90 days [38]. Moreover, because LTVADs only support the left ventricle, one of the 
critical points to take into consideration is the potential right ventricular failure (RVF) after 
MCS is initiated. Nowadays, there are no comprehensively evaluated tools to predict RVF, but 
some hemodynamic and echocardiographic parameters might be useful. Concerning hemo-
dynamic evaluation, a right ventricular stroke work index less than 250 mmHg·mLm2 [39], 
right atrial pressure > 15 mmHg and central venous pressure/PCWP >0.63 are considered 
important risk factors of RVF [40]. Echocardiographic parameters include tricuspid annular 
motion (TAPSE) < 7.5 mm [41], right ventricular to left ventricular end diastolic diameter 
ratio > 0.72 [42], severe tricuspid regurgitation, right ventricular short/long axis ratio > 0.6 [43] 
and right ventricular free wall strain [44]. A biventricular approach using continuous blood 
flow pumps has recently been reported with limited success considering the significant num-
ber of adverse events during follow-up [45].
Finally, it is very important to ensure optimal patient’s self-care training by specialized nurses, 
and appropriate follow-up is indispensable for the success of a LTVAD program. Daily care 
of the device, especially considering the correct management of the driveline wound is of 
paramount importance to avoid infection. Moreover, the correct management of concomitant 
cardiovascular risk factors such as hypertension or diabetes, and other comorbidities is also a 
relevant issue in these patients that should be pursued.
4. Inclusion in heart transplant waiting list
The decision of including a patient in the HTx waiting list is not easy and should be taken 
together by a medical and surgical team, in a case-by-case comprehensive evaluation. Only 
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stage D HF patients without any other treatment option should be evaluated for HTx, because 
of the shortage of organs, the intrinsic risk of surgery, and the risk of rejection and complica-
tions due to immunosuppressant therapy. Table 3 shows the indications for HTx.
Therefore, it is important to undergo an exhaustive study of the patient before listing for HTx, 
in order to exclude any significant risk factor that might compromise outcomes after HTx. 
Last but not least, the patient must be motivated, well informed and in an optimal psychologi-
cal state to follow the intensive pharmacologic treatment that follows the HTx. Table 4 shows 
recommended studies that should be done when evaluating candidacy for HTx.
To conclude, patients with LTVAD as BTC can be included in the waiting list once reversible 
PHT is confirmed by a right heart catheterization, and/or there is significant improvement 
in renal function (glomerular filtration rate [GFR] > 30 cc/min/1.73 m2, especially if there is 
no evidence of intrinsic renal damage: absence of significant proteinuria without significant 
abnormalities in renal ultrasonography), and other parameters. In patients with concomitant 
treated malignant neoplasm, a thoughtful evaluation tackling life expectancy and relapse pos-
sibilities, together with an oncologist's evaluation should be performed before listing for HTx.
Absolute Indications
1. Hemodynamic compromise due to HF
· Refractory cardiogenic shock
· Documented dependence on IV inotropic support to maintain adequate organ perfusion
2. Peak VO2 less than 14 mL per kg per minute with achievement of anaerobic metabolism or less than 12 mL per kg 
per minute with the use of β-blockers
3. Severe symptoms of ischemia that consistently limit routine activity and are not amenable to coronary artery bypass 
surgery or percutaneous coronary intervention
4. Recurrent symptomatic ventricular arrhythmias refractory to all therapeutic modalities
Relative Indications
1. In the presence of sub-maximal cardiopulmonary exercise test (RER˂1.05), ventilation equivalent of carbon dioxide 
(VE/VCO2) slope > 35
2. Use of prognostic scores in conjunction with cardiopulmonary exercise stress test. A 1-year estimated survival cal-
culated by the SHFM less than 80% and a HFSS in high/medium risk range
3. Recurrent unstable ischemia not amenable to other intervention
4. Recurrent instability of fluid balance/renal function not due to patient noncompliance with medical regimen
Insufficient indications
1. Low left ventricular ejection fraction
2. History of NYHA functional class III or IV symptoms of HF
3. Peak VO2 greater than 15 mL per kg per minute (and greater than 55% predicted) without other indications
V02: Oxygen consumption; SHFM: Seattle Heart Failure Model; HFFS: Heart Failure Survival Score; NYHA: New York 
Heart Association.
Table 3. Heart transplant indications (Source Kirklin JK et al. and Hunt S et al. [46, 19]).
Heart Transplantation20
4.1. Immune suitability evaluation
Screening for humoral rejection is done through the panel-reactive antibody (PRA) test, which 
determines the presence of circulating anti-HLA antibodies. With this cytotoxic test, it is pos-
sible to estimate the sensitization of the recipient by the percentage of the serum reactiv-
ity that activates complement against a panel of the most common HLAs in the recipient’s 
country. A PRA > 10% is considered positive and is a relative contraindication for HTx. In 
these cases, it is recommended to perform a prospective cross-match between the lympho-
cytes of the donor and recipient’s serum before HTx. Currently, it is also possible to identify 
• Clinical history and complete physical examination
• Size/weight/body mass index
• Blood Typing and Immune suitability study
· ABO blood group
· HLA typing
· Panel-reactive antibody (PRA)
· Flow cytometry (Luminex)
• Assessment of severity of cardiac insufficiency
• Multiple organ function evaluation
· General analysis with glycemia, lipid profile, renal function, 
hepatic profile, coagulation, thyroid hormones, natriuretic 
peptides
· First-hour urinalysis with proteinuria
· Chest x-ray
· Functional respiratory tests with arterial gases
· Abdominal ultrasound or thoraco-abdominal CT scan
· Doppler echo of supra-aortic trunks (if more than 50 years, 
diabetic, ischemic cardiomyopathy or clinical suspicion)
· Lower extremity ankle/arm or Doppler echo index (if more than 
50 years, diabetic, ischemic cardiomyopathy or clinical suspicion)
· Electroencephalogram
· Bone densitometry (if more than 50 years, woman or clinical 
suspicion)
• Infectious assessment
· Hepatitis B virus: surface antigen, antibody of 
surface, anti-core
· Antibody hepatitis C virus
· Antibody hepatitis A virus
· Human immunodeficiency virus
· VDRL (venereal disease research laboratory)





· Tuberculin or quantiferon test
• Vaccination
· Influenza (annual)
· Hepatitis B and A if it has not been done
· Pneumococcal vaccine (every 5 years)
• Study of hidden malignant neoplasm
· Fecal occult blood test × 3
· Colonoscopy (if >50 years old)
· Mammography (if indicated or > 40 years)
· Gynecological examination and vaginal cytology 
(if >18 years old and sexually active)
· Specific prostate antigen and rectal examination 




· Psychosocial and economic assessment
HLA: human leucocyte antigen and CT: computerized tomography.
Table 4. Recommended studies in the evaluation of candidates for HTx. Adapted from Mehra et al. [29].
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and quantify the amount of antibodies against surface HLA antigens using a flow cytometry 
immunofluorescence technique. This method (Luminex) is much more sensitive than the PRA 
and allows a better assessment of the risk of positive cross-reactivity at the time of HTx and 
eventual humoral rejection.
Patients can be sensitized after pregnancies, blood transfusions, after previous transplanta-
tion or after the implant of a ventricular assist device, although sometimes there is no obvious 
sensitizer event, and it is thought to be due to cross-reactivity between bacterial or viral epit-
opes and HLAs. In case that the recipient has a ventricular assist device, it is recommended to 
repeat the PRA and flow cytometry every 2–3 months. If blood transfusions are required, the 
PRA and flow cytometry should be repeated 2 weeks after the transfusion and each month 
during 6 months [29].
The presence of anti-HLA antibodies with high levels of median fluorescent intensity or MFI 
(units used to quantify antibodies), usually over 3000–5000, depending on the immunology 
laboratory, is considered potentially cytotoxic. By this technique it is also possible to obtain a 
calculated PRA (cPRA), which gives the percentage of unacceptable HLAs in the donor popu-
lation. For example, if the cPRA is 80%, it means that only 20% of all possible donors in this 
specific population will be compatible with the receptor. Although the cPRA cut-points are 
not clearly established, some authors consider an absolute contraindication if cPRA is above 
50–70%, and thus recommend a desensitization therapy before HTx [47]. In these cases it is 
also necessary to perform a virtual cross-match at the time of HTx, consisting of the evaluation 
of anti-HLA receptor antibodies titters relative to the donor HLA. If the virtual cross-match is 
positive, the risk of hyperacute rejection is very high and the donor organ must not be accepted.
5. Infectious evaluation and vaccination
A complete serologic status of the potential recipient should always be obtained before HTx, 
especially considering previous exposure to cytomegalovirus and Mycobacterium tuberculo-
sis, as it is crucial when defining infectious prophylaxis after HTx.
The human immunodeficiency virus infection with undetectable viral load is not a contrain-
dication to HTx at present, although each case must be assessed individually and retroviral 
treatment should be adapted to avoid interference with calcineurin inhibitors [48].
Patients with chronic hepatitis B infection (defined by the presence of hepatitis B surface anti-
gen) have equal survival rates compared to the rest of the cohort, unless there is significant 
liver disease. In this setting, liver cirrhosis should be ruled out with biopsy if necessary, and 
antivirals should be given in order to lower viral load, since there is a risk of reactivation of 
the disease with immunosuppression after HTx. Similarly, when hepatitis C virus serology 
is positive, the quantitative viral load and degree of liver disease must be determined. If cir-
culating HCV is detected, the disease is active and antiviral treatment must be prescribed to 
eliminate the virus. An altered hepatic function, which is not justified by HF, or a liver biopsy 
with evidence of cirrhosis, should be considered an absolute contraindication [30].
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Finally, vaccination against hepatitis A and B viruses is also recommended if not previously 
given, as well as vaccination against Pneumococcus (every 5 years), Influenza (annual) and 
Haemophilus influenzae before the HTx [29].
6. Risk factors and contraindications
Absolute contraindications for HTx are progressively diminishing because of the improved 
treatment strategies both for comorbidities and immunosuppressive therapies after HTx, so 
nowadays it is preferable to talk about risk factors that increase post-HTx morbidity and mor-
tality than contraindications. According to the latest recommendations from the ISHLT [19] 
the most important HTx risk factors are classified in Table 5. Nonetheless, it is important to 
especially consider the following:
• Patients with age > 70 years could be considered for HTx based on individual evaluation. It 
is important to take into consideration that this population has lower rates of rejection but 
higher mortality than younger patients.
• Patients with a body mass index (BMI) > 35 kg/m2 should wait until they achieve a 
BMI ≤ 35 kg/m2 to be included in the waiting list, because patients with BMI > 35 kg/m2 
have more difficulty in finding an adequate donor. Besides, there is some evidence that this 
group of patients have an increase in post-operative morbidity and mortality.
• Poorly controlled diabetes (glycosylated hemoglobin [HbA1c] >7.5% or 58 mmol/mol) with 
end-organ damage (other than non-proliferative retinopathy) is a relative contraindication 
for HTx.
• Presence of irreversible renal dysfunction with GFR <30 cc/min/1.73 m2 should be con-
sidered a relative contraindication for HTx alone, although the combination of heart and 
kidney transplant could be considered.
• Clinically severe symptomatic cerebrovascular disease could be considered a contraindi-
cation for HTx based on the existence of a study that shows how these patients have an 
increased risk of stroke and functional decline as an independent variable after transplan-
tation [49]. Peripheral vascular disease that limits rehabilitation without possibility of re-
vascularization continues to be a contraindication.
• Frailty defined as a clinically identifiable disorder of amplified vulnerability of age-related 
decline in reserve and function across multiple physiologic systems brought on with minor 
stressors [50] should be assessed before HTx, the presence of three of five possible symp-
toms, including unintentional weight loss of 5 kg within the past year, muscle loss, fatigue, 
slow walking speed and low levels of physical activity define a fragile patient.
• Psychosocial evaluation previous to HTx is important in order to make sure that the patient 
is going to be able to accomplish an optimal care after transplantation. Absence of this con-
dition is considered a relative contraindication.
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7. Heart transplantation waiting list priority
Nearly 100,000 people worldwide have received a new heart since the first HTx 50 years ago, 
8000 of them in Spain, which makes it a country with a remarkable experience [52]. Each year 
priority criteria on the waiting list are reviewed. The 2017 priority criteria in adult population 
in Spain are summarized in Table 6.
The objective of this model is to prioritize those patients in the most critical situation. The 
ASIS-TC study showed a median waiting time for patients in urgency Grade 0 of 7.6 days 
allowing HTx in nearly 80% of this population [34]. Other countries like the U.S have a more 
heterogeneous group of patients listed in emergency situation (Status 1A) (Table 7), which 
makes waiting times more prolonged, between 47 and 413 days, depending on the region 
Absolute contraindications
• Systemic disease with life expectancy <2 years:
· Active neoplasm (if preexisting, evaluation with an oncology specialist is necessary to stratify the risk of recurrence 
and establish a time to wait after remission)
· Systemic disease with multi-organ involvement (systemic lupus erythematosus, amyloidosis, sarcoidosis)
· Severe chronic obstructive pulmonary disease (FEV1 < 1 L)
· Renal or hepatic severe dysfunction, if associated renal or liver transplant is not performed
• Irreversible pulmonary hypertension
· Pulmonary artery systolic pressure > 50 mmHg
· Transpulmonary gradient >12 mmHg
· Pulmonary vascular resistance >3 Wood units despite treatment
Relative contraindications
• Age > 70 years (carefully selected patients may be considered)
• Diabetes with end-organ damage (except non-proliferative retinopathy) or persistent poor glycemic control 
(HbA1c > 7.5%) despite treatment
• Active infection, except VAD infection. Patients with HIV, hepatitis, Chagas disease and tuberculosis can be 
considered with strict management
• Severe peripheral arterial or cerebrovascular disease not suitable for treatment
• Other serious comorbidities with poor prognosis, such as neuromuscular diseases
• Obesity: BMI > 35 kg/m2
• Cachexia: BMI < 18 kg/m2
• Frailty: when three of five possible symptoms (including unintentional weight loss of >5 kg within the past year, 
muscle loss, fatigue, slow walking speed, and low levels of physical activity) are present
• Current tobacco, alcohol or drug abuse
• Insufficient social support
• Elevated panel-reactive antibody test defined as >10%
FEV1: forced expiratory volume in 1 s; VAD: ventricular assist device; HIV: human immunodeficiency virus; BMI: body 
mass index.
Table 5. Contraindications for heart transplant (Source Sanchez-Enrique et al. [51]).
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[47]. This shows the importance of defining homogeneous criteria to define each stage of 
classification for HTx waiting list, especially in the setting of emergency. A new more precise 
classification for the U.S. is expected to be published in 2018.
Urgency Grade 0: national (priority over the rest of grades)
• Patients with STVAD of complete supporta.
• Patients with extracorporeal membrane oxygenation (ECMO) or partial support STVAD for at least 48 hours if 
there is no evidence of multi-organ failureb,c.
• Patients with dysfunctional LTVADd secondary to mechanical dysfunction or thromboembolism.
Urgency Grade 1: regional (priority over elective patients in reference zone)
• Patients with a normally functioning external LTVADe.
• Patients with dysfunctional LTVAD secondary to driveline infection, gastrointestinal bleeding or right heart 
failure.
Elective
• Patients not included in Grade 0 or Grade 1 categories.
STVAD: short-term ventricular assist device; LTVAD: long-term ventricular assist device.ae.g., Levitronix Centrimag.
be.g., Impella CP, Impella 5.0, Tandem Heart.
cMaximum time in urgency Grade 0 will be 7 days, once this time has passed the patient will be in Urgency Grade 1.
de.g., BerlinHeart Excor, Hearmate II, Heartmate 3, Heartware HVAD.
ee.g., BerlinHeart Excor.








• Continuous infusion of a single high-dose intravenous inotrope or multiple intravenous inotropes, and 
with continuous hemodynamic monitoring of left ventricular filling pressures
• LVAD, RVAD, or BiVAD for 30 days
• Mechanical circulatory support with significant device-related complications (thromboembolism, 
device infection, mechanical failure, or life threatening ventricular arrhythmias)
Status 1B • Uncomplicated LVAD, RVAD, BiVAD after 30 days have been used.
• Outpatient TAH
• Continuous infusion of intravenous inotropes
Status 2 • Candidates not meeting 1A or 1B criteria
Status 7 • Temporarily inactive, most often due to infection
BiVAD: biventricular assist device; ECMO: extracorporeal membrane oxygenation; IABP: intra-aortic balloon pump; 
LVAD: left ventricular assist device; RVAD: right ventricular assist device; TAH: total artificial heart.
Table 7. Status codes for heart transplantation in U.S. (Source Kittleson et al. [47]).




Cardiovascular diseases are the main cause of death around the world, and with the improve-
ment in therapeutics leading to an increase of life expectancy it is probable that we will see 
increasing number of patients with HF. Also, prevalence of HF in the overall population 
ranges between 1 and 2% depending on the country. Therefore it is expected that the number 
of patients with AHF will continue rising after this review. Yet it is important keep in mind 
some concepts:
• Establishing HF etiology could play a key role in the management and prognosis of the 
patient and his family, especially if there is an identified genetic cardiomyopathy.
• NYHA scale is useful to determine functional capacity, however objective tests should be 
used in order to establish a more reliable prognosis in this population.
• Optimization of HF treatment with medication and devices according to the latest guide-
lines is mandatory before considering advanced therapies.
• LTVADs as BTT or BTC is an appropriate management strategy in selected cases, especially 
if they are in an INTERMACS 3 profile.
• HTx remains the optimal therapy for patients in stage D HF, however with the shortage of 
donors and the improvement in technology, LTVADs as DT might change the management 
strategy in developed countries.
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AHF: advanced heart failure
CS: cardiogenic shock
VAD: ventricular assist device
MCS: mechanical circulatory support
BTT: bridge to transplant
BTC: bridge to candidacy
BTD: bridge to decision
STVAD: short-term ventricular assist device
LTVAD: long-term ventricular assist device
BTR: bridge to recovery
DT: destination therapy
NYHA: New York heart association
PCWP: pulmonary capillary wedge pressure




CPET: cardiopulmonary exercise testing
VO2: oxygen uptake
VE/VC02: ventilation to carbon dioxide slope
RER: respiratory exchange ratio
6’WT: 6-minute walking test
SHFM: Seattle Heart Failure Model
HFSS: heart failure survival score
INTERMACS: Interagency Registry for Mechanically Assisted Circulatory Support
PHT: pulmonary hypertension
PGF: primary graft failure
RVF: right ventricular failure
SPAP: systolic pulmonary arterial pressure
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MPAP: mean pulmonary arterial pressure
CO: cardiac output
TPG: transpulmonary gradient
PVR: pulmonary vascular resistance
ISHLT: International Society of Heart and Lung Transplantation
BMI: body mass index
HLA: human leucocyte antigen
PRA: panel-reactive antibody
BiVAD: biventricular assist device
ECMO: extracorporeal membrane oxygenation
IABP: intra-aortic balloon pump
LVAD: left ventricular assist device
RVAD: right ventricular assist device
TAH: total artificial heart
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